Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70208-0 ◽

2014 ◽

Vol 2 (5) ◽

pp. 369-384 ◽

Author(s):

Anthony H Barnett ◽

Ambrish Mithal ◽

Jenny Manassie ◽

Russell Jones ◽

Henning Rattunde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718462631.793518344 ◽

2016 ◽

Author(s):

Sydney Tang ◽

Gary Chan

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30086-5 ◽

2019 ◽

Vol 7 (6) ◽

pp. 429-441 ◽

Author(s):

Carol Pollock ◽

Bergur Stefánsson ◽

Daniel Reyner ◽

Peter Rossing ◽

C David Sjöström ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/review2 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients with Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism ◽

10.31031/gjem.2018.02.000543 ◽

2018 ◽

Vol 2 (4) ◽

Author(s):

Davis Townsend

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/review3 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text